Mathew Cherian
Biochemistry, Genetics and Molecular Biology · The Ohio State University
Publications
134
Citations
1,504
Est. group size
~37
Recurring co-author estimate
Active years
21
Publishing since 2005
Mathew Cherian appears in publication records primarily connected to clinical and translational research on hormone receptor-positive breast cancer, including studies on drug combinations like palbociclib, abemaciclib, and lasofoxifene for treating metastatic disease. The publication list also includes a variety of unrelated clinical and technical topics (e.g., radiology, epidemiology, cryptography), suggesting this name may be associated with multiple collaborative studies or possibly multiple individuals sharing the same name in the record. Prospective students should note the breast cancer clinical trial work as the most consistent thread across the recent publication history.
Publication output grew substantially from 2017-2020, peaked around 2020-2023 with roughly 19-22 papers per year, and has since moderated to about 12-14 papers per year in 2024-2025.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Venous Congestion in Transmesenteric Hernia After Superior Mesenteric Artery Stenting for Chronic Mesenteric Ischemia
Cureus · 2025
- Gender Differential Prevalence of Overweight and Obesity, Hypertension and Diabetes in South India: A Population-Based Cross-Sectional Study
Global Heart · 2024
- Enhanced cryptography techniques using inherited process with cyclic crossover operation in big data
Advances in Complex Systems · 2024
- Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2− breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2
Annals of Oncology · 2023
- Operational Metrics for the ELAINE 2 Study Combining a Traditional Approach With a Just-in-TIME Model
JCO Clinical Cancer Informatics · 2023
- Lasofoxifene (LAS) plus abemaciclib (Abema) for treating <i>ESR1</i>-mutated ER+/HER2- metastatic breast cancer (mBC) after progression on prior therapies: ELAINE 2 study update.
Journal of Clinical Oncology · 2023
- A phase II trial of an alternative schedule of palbociclib and embedded serum TK1 analysis
npj Breast Cancer · 2022
- A 10-miRNA risk score-based prediction model for pathological complete response to neoadjuvant chemotherapy in hormone receptor-positive breast cancer
Science China Life Sciences · 2022
- DWI-FLAIR Mismatch in Stroke: “P.S.” (Partial Strategic Concept) for Clinical Practice
Journal of Stroke Medicine · 2022
- The role of third-generation dual-source dual-energy computed tomography in characterizing the composition of renal stones with infrared spectroscopy as the reference standard
Polish Journal of Radiology · 2022
- Operational metrics for the ELAINE II study combining a traditional approach with a just-in-time model.
Journal of Clinical Oncology · 2022
- Gender differential prevalent of overweight and obesity, hypertension and diabetes in South India: A population-based cross-sectional study
Research Square · 2022
- Comparison of Turbo Flash and dual-energy modes of third-generation dual-source CT in pre-transplant renal angiography: a prospective observational study
The Egyptian Journal of Radiology and Nuclear Medicine · 2022
- An Effective Remedy To The Weaknesses Of WebCaches In HTTP Flooding
2022
- Abstract PS12-02: Safety and efficacy of an alternative schedule of palbociclib (PAL) in hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC) and the utility of serum thymidine kinase 1 (sTK1) activity in predicting PAL response
Cancer Research · 2021
- Cancer Research×21
- Journal of Clinical Oncology×13
- Research Square×6
- bioRxiv (Cold Spring Harbor Laboratory)×6
- Clinical Cancer Research×5
- Julie Stephens
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Nicole Williams
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Bhuvaneswari Ramaswamy
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Kai Johnson
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Emily Burke
Biochemistry, Genetics and Molecular Biology · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile